Screening of antimalarial drugs: An overview

Efforts to discover and develop new antimalarial drugs have increased dramatically in recent years mainly because of resistance to existing antimalarial drugs. Selection of candidate drugs for clinical trials in man and the design of clinical protocols are based upon consideration of data from a bat...

Full description

Saved in:
Bibliographic Details
Published in:Indian journal of pharmacology 2006-01, Vol.38 (1), p.5
Main Authors: Kalra, B, Chawla, S, Gupta, P, Valecha, N
Format: Article
Language:English
Subjects:
Antimalarials
Case studies
Evaluation
Malaria
Primates
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Efforts to discover and develop new antimalarial drugs have increased dramatically in recent years mainly because of resistance to existing antimalarial drugs. Selection of candidate drugs for clinical trials in man and the design of clinical protocols are based upon consideration of data from a battery of preclinical test systems. All compounds are assessed initially in one or more primary screening models. A compound which is considered 'active' by well established criteria in primary screening test is considered for further evaluation in successively more clinical tests. At the end of each stage of testing, a decision is taken to advance the compound to the next stage or discontinue it. Primary screening tests should have optimal sensitivity, a high degree of reproducibility, high throughput, requiring a minimum quantity of test compound and should bear low cost. As there is growing need for newer and more efficacious antimalarial drugs especially in tropical countries, more sensitive and economical screening models are needed. This review is an update of various conventional and latest in vitro and in vivo screening methods being used for evaluation of antimalarial compounds.
ISSN:0253-7613
1998-3751
DOI:10.4103/0253-7613.19846